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INTRODUCTION
Up-to-date treatment of diabetes of type 1 and type 2 re-
quires therapeutic intervention which not only allows to sur-
vive and avoid acute symptoms, but also prevents developing 
late complications. The cost of diabetes treatment represents 
a significant financial burden for every developed country 
budget with predominant costs of chronic complications treat-
ment. It is a well-known fact that late complications of diabe-
tes develop as a consequence of an insufficient glucose blood 
level compensation. The basic parameter used in evaluation of 
the metabolic balance is a proportion of glycosylated hemoglo-
bin (HbA1c). The parameter most appropriately correlates with 
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the mean glycemia level during the last three months. The 
majority of the guidelines suggest HbA1c monitoring twice a 
year, so the only advantage is a possibility to evaluate suc-
cess or failure of the therapy, with no usefulness in adaptation 
of treatment to the unstable glucose blood level. A propor-
tion of HbA1c is linked with the mean glucose blood level and 
does not reflect a diurnal glycemia fluctuation. Monnier et 
al. presented a percentage of fasting and postprandial glyce-
mia depending on HbA1c in a large group of patients with 
type 2 diabetes. Fasting glycemia turned out to be crucial in 
the worst controlled patients. The diurnal glycemia predomi-
nates when HbA1c is lower than 8.5% [1]. The postprandial 
period includes several hours after a meal when the glucose 
concentration reaches the highest value in 24 hours. The glu-
cose blood level evaluation is not performed in that period 
and the treatment is not adjusted to this value. However there 
is a large body of evidence indicating that even a relatively 
short-lasting high postprandial glucose level may influence the 
development of particularly microangiopathic complications, 
regardless of the overall glucose balance estimated by HbA1c. 
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In this review the authors discuss pathophysiology, epidemiol-
ogy and clinical aspects concerning reciprocal relationship of 
postprandial glycemia (PPG) and atherosclerosis and ischemic 
heart disease development.
The β cell disorder and pathophysiology of 
postprandial period
Adequate insulin secretion by b cells ensures the mainte-
nance of glucose level in a normal range. That precise mecha-
nism fails in millions of patients resulting in diabetes devel-
opment. In type 1 diabetes the absolute insulin baseline and 
postprandial deficiency is observed. The majority of cases had 
type 2 diabetes. In the pathogenesis the two main defects such 
as impairment of insulin secretion and reduced insulin sensi-
tivity have been observed. The cases of type 2 diabetes are of 
a wide range: from insulin resistance predominance coexisting 
with relative insulin deficiency to predominant secretion de-
fect with slight insulin resistance. 
There are some significant questions concerning impair-
ment of insulin secretion in type 2 diabetes. What is a share 
of the b cell disorder and insulin resistance in pathophysiology 
of type 2 diabetes in consecutive stages of the disease? Does 
impairment of insulin secretion is a consequence of loss of cell 
mass or of the b cell disorder? In clinical practice the diabetes 
type 2 is of multifactorial origin. The impairment of insulin 
secretion with concomitant insulin resistance forms the clini-
cal picture of the disease development (fig.). 
In the first stage of type 2 diabetes increasing insulin resis-
tance is accompanied by increase of insulin secretion. As long 
as the b cell compensation mechanism remains efficient the 
glucose level stays normal. On a certain disease period the b 
cell disorder begins to escalate and the diabetes starts to mani-
fest itself clinically. It is worth mentioning that some impor-
tant trials in patients with type 2 diabetes (int. al. the United 
Kingdom Prospective Diabetes Study) showed intensifying 
insulin secretion impairment and stable insulin resistance in a 
fully developed disease [2,3]. 
Impairment of insulin secretion in diabetes type 2 patients 
can be demonstrated in several ways. The very early disorder 
which reveals in the beginning of the disease is the first phase 
insulin secretion decline indicated by the intravenous glucose 
tolerance test (IVGTT). In the later disease phase delayed and 
decreased insulin secretion in the late secretion phase after 
glucose load in the oral glucose tolerance test (OGTT) or after 
a composed meal is observed. In a very advanced phase of the 
disease the insulin secretion remains at a very low baseline 
level [4]. 
It is worth mentioning that in type 2 diabetes impairment 
of the normal glucose oscillation is observed [5]. It becomes ir-
regular and of low amplitude. A decrease of the proportion of 
insulin in a cell secretion product (with increase in proinsulin) 
is noted [5]. Incretin secretion is also impaired [6]. 
Considering the decrease of insulin secretion the question 
should be raised - to what degree it depends on reduced b cell 
mass and to what degree on its impaired function. It seems 
that the two phenomena coexist and they are both essential for 
the disease development. In the autopsies of the diabetic pa-
tients and in animal models the 30–50% decrease of the b cell 
number and amyloid accumulation is observed [6­8]. How-
ever, that does not explain increased damage. Impairment of 
those b cells which survived the initial disease phase is equally 
important. Several lines of evidence showed multifunctional 
impairment of b cells, and importantly, the phenomenon is 
partially reversible [9].
Hyperglycemia is essential in the etiology of micro- and 
macroangiopathies. In the recent years the toxicity of major 
diurnal glucose level fluctuation as well as the unfavorable in-
fluence of excessive postprandial glucose level increase have 
been emphasized [9]. The postprandial glycemia level depends 
on many factors such as pre-prandial glycemia, kind of food 
and carbohydrates content, stomach motor activity, efficien-
cy of neurohormonal system and incretin secretion, mainly a 
peptide-inhibitor of gastric secretion, secretin, cholecystoki-
nin, gastrin and glucagon-like peptide-1. For the postprandial 
glycemia the normal initial phase of insulin secretion after an 
alimentary stimulus, glucagon concentration and uptake, and 
metabolism of glucose in the liver and peripheral tissue are 
of great importance. Carbohydrate and lipid metabolisms are 
closely associated and decide on the energetic balance of the 
body. During the development of diabetes this mechanism is 
unsettled, which results in postprandial hyperglycemia and 
hyperlipidemia [9]. 
Food is the main and natural source of energy. Carbohy-
drates, lipids and proteins are the basic nutritive substances 
which, after being digested in gastrointestinal tract, are ab-
sorbed in blood or lymph. The resorption follows the food up-
take with the lasting time depending mainly on the content 
and type of carbohydrates and lipids in a meal. After a carbo-
hydrates­rich meal the resorption period comes to 2–3 hours, 
after a mixed meal 3–5 hours, and after a lipid­rich meal ­ 
8–10 hours [10,11]. 
Glucose or lipid excess is a very unfavorable phenomenon 
leading to impaired interaction between inflammatory re-
sponse cells and endothelium [12]. It is shown that postprandi-
al hyperglycemia and free fatty acids increase are accompanied 
by inflammatory reaction and oxidative stress [13,14]. The 
sources of increased reactive oxygen species (ROS) production 
in hyperglycemia and hyperlipidemia are glycolytic pathway 
and b­oxydation of fatty acids in endothelial cells [12]. The 
main sources of ROS represent stimulated neutrophils. In 
diabetic patients these cells reveal subliminal activation and 
release the excess of peroxide anions and hydrogen peroxide 
in a resting state [15]. It was proved that the neutrophil ROS 
release increases with postprandial hyperglycemia [16]. The 
oxidation stress in diabetic patients is a result of increased 
ROS production as well as insufficient oxidation mechanisms. 
The main role in this regulation is attributed to superoxide 
dismutase (SOD), catalase and gluthation complex (reduced 
glutation, peroxidase, glutation reductase). In diabetic pa-
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tients, even if well metabolically controlled, the SOD activa-
tion and the glutation bioavailability decrease were observed 
[17]. It was proved that enhancement of postprandial oxida-
tive stress depends on the kind of food. Highly caloric foods 
rich in carbohydrates with high glycemic index and saturated 
fatty acids seem to be the most unfavorable and toxic for endo-
thelium [14]. Increased ROS production is linked with protein 
kinase C, active forms of nicotinamide adenine dinucleotide 
phosphate (NAD(P)H) and nuclear transcription factor kappa 
B activation [12,13,18]. These molecules play a key role in the 
inflammatory state cascade, which is essential in diabetes and 
in micro­ and macroangiopathic chronic complications [19]. 
Pathophysiologically, the reduction of glucose level in-
crease as well as the postprandial glucose level reduction seem 
to be reasonable.
Postprandial glycemia and cardiovascular 
complications
In 1997 the American Diabetes Association (ADA) and 
World Health Organization (WHO) modified the diagnostic 
criteria for diabetes by decreasing the normal lower border of 
fasting glucose level from 140 to 126 mg%. Moreover, the new 
term, i.e. impaired fasting glucose (IFG) was accepted and the 
WHO indicated the necessity of supporting the OGTT in 
doubtful cases:
1) fasting plasma glucose (FPG) between 110–125 mg/dl,
2) elderly patients with normal weight, a high risk of diabetes 
and normal FPG [20, 21].
After the new criteria were published a debate started 
about the relation between fasting glucose level and postpran-
dial glycemia in the identification of diabtes in a high-risk 
population. The most important issue is how fasting and post-
prandial hyperglycemia determine the patient’s general condi-
tion and death risk. The issue was analyzed in the DECODE 
trial [22]. 
The analyzed data lead to the conclusion that when the 
glucose intolerance diagnosis was based on the fasting glucose 
level, patients with previously diagnosed diabetes were in the 
worse prognosis group than those who were newly diagnosed. 
If the only disorder was the elevated fasting glucose level the 
prognosis was similar to those with no glucose tolerance dis-
order. For a change, if the glucose tolerance disorder diagno-
sis was based on the 2-hour postprandial blood glucose test, 
prognoses on survival of patients were worse in both groups. 
Moreover, 31% of patients with diabetes diagnosed by the 
2-hour postprandial blood glucose test had normal fasting 
glucose test results. In this group of patients death risk was 
increased (relative risk 1.8 in men and 2.6 in women). The 
death risk was significantly higher in patients with impaired 
glucose tolerance (glycemia 140–200 mg% in OGTT) and a 
normal fasting glucose test. Therefore the fasting glucose test 
does not allow the straightforward identification of the group 
of patients in high risk of premature death. The FPG does not 
show an independent association with mortality, however the 
2-hour postprandial blood glucose test is an independent mor-
tality predictor after fasting glucose correction [23].
Thus it should be emphasized that the presented analy-
sis was not dedicated to the verification of current diagnostic 
criteria, but to defining the high risk group of patients with 
diabetes type 2. The probability of normal FPG was higher in 
the young and obese diabetic patients, whereas the older and 
slim patients more likely meet the 2-hour postprandial blood 
glucose criterion.
The DECODE observation initialized a new direction in 
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Fig. Reciprocal relationship of 2 main patho-
physiologic defects in natural history of dia-
betes type 2 (according to the International 
Diabetes Center [IDC]. Minneapolis, Minne-
sota). IGT – impaired glucose tolerance
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currence and progression, indicating the significance of post-
prandial glucose. The conclusions, for the European popula-
tion, were confirmed in other epidemiological studies [24,25]. 
The independent connection between postprandial glucose 
and newly diagnosed diabetic patients mortality was observed 
in an 11-year prospective observation - the Diabetes Interven-
tion Study. The study shows that incidence of myocardial in-
farction in patients with postprandial glucose above 180 mg% 
(10 mmol/l) was 40% higher than in patients with postpran-
dial glucose below 144 mg% (8 mmol/l). The key role in the 
evaluation of new diagnostic criteria value has the cause-effect 
link between hyperglycemia and cardiovascular diseases [26]. 
The Hoorn study showed the increasing cardiovascular risk 
in FPG equal to or above 110 mg% (6.1 mmol/l). Moreover, 
in non-diabetic patients without any cardiovascular diseases, 
the two standard deviations increase in the WHO glucose 
test predicted 2.24-fold increase of the total mortality relative 
risk and 3.4­fold increase of the cardiovascular mortality risk 
comparing with the general population [27]. The correlation 
remained statistically significant after including known car-
diovascular risk factors.
Similarly, the Honolulu Heart Study and the Rancho Ber-
nardo Study indicate a continuously increasing risk of coronary 
heart disease, while increased postprandial glucose levels were 
observed [28,29]. Another study, the Funagata Study, after 7 
years of prospective observation, proved the impaired glucose 
tolerance instead of the abnormal FPG to be a cardiovascular 
risk factor [30]. 
In summary, more and more data suggest that both fast-
ing and postprandial hyperglycemia are vascular pathology 
risk factors with the continuous risk increase. The 2-hour post-
prandial blood glucose identifies patients with the increased 
cardiovascular risk, not identified with the FPG test. 
The review of studies concerning the causality between 
postprandial glycemia and cardiovascular disease is shown in 
table 1 [31]. 
The significance of postprandial hyperglycemia has to 
be confirmed in interventional studies to prove whether the 
postprandial glycemia normalization strategy is superior to 
the previous one focused on fasting and preload glycemia nor-
malization. In chronic diseases unequivocal results may be ob-
tained in long-term controlled clinical studies. By the time of 
an unequivocal confirmation in the interventional studies, the 
postprandial glucose normalization strategy in everyday clini-
cal practice seems to be reasonable. 
The de Vecciana et al. study [32] is the so far only study 
showing normalization of postprandial glycemia to be a predic-
tor of diabetes compensation and reduction of diabetes-related 
pregnancy and perinatal complications. The study included 
66 pregnant women with diabetes, requiring insulinotherapy 
before 30 weeks of pregnancy. The participating women were 
divided in two groups: in the first group the preload glucose 
was monitored and in the second group the FPG – 1 hour after 
each meal. In the group with postprandial glucose monitoring 
better metabolic compensation, less caesarian sections because 
of feto-pelvic disproportion and higher insulin requirement 
were observed. However, in the newborns of postprandial 
monitored mothers, the lower birth weight and less frequent 
hypoglycemia were observed. The beneficial effect was ob-
tained by modification of the glucose level monitoring leading 
to insulinotherapy intensification in well-educated patients 
(significant higher insulin dose). In the study the two monitor-
ing plans, not the therapeutic interventions were compared. 
However, it may be assumed that postprandial monitoring 
convinced the patients to adequately higher insulin injections.
The data obtained may not be extrapolated to late diabe-
tes complications which occur after longer than the mentioned 
time of observation and require a long-term clinical study. On 
the other hand, in the presented study, a significant clinical 
improvement was obtained in a small group of patients and in 
a relatively short follow-up. 
Practical aspects
Intensive treatment of diabetes with maintaining ap-
propriate low glucose levels allows decreasing micro- and 
macroangiopathic complication risk. The best outcome is to 
achieve glucose levels in a normal range. Currently, glycosyl-
ated hemoglobin (HbA1c) constitutes the main parameter to 
determine diabetes compensation. The Diabetes Association 
treatment guidelines include HbA1c as recommended target 
values. In the European Association for the Study of Diabe-
tes (EASD) and the ADA 2006 joint guidelines the recom-
mended HbA1c level is below 7% [33]. The Polish Diabetes 
Association recommends lower values ≤6.55 or even ≤6.1% 
[34]. The HbA1c value reflects the mean glucose level dur-
ing the last 8 weeks. The HbA1c is influenced by the noctur-
nal blood glucose, preload and postprandial glucose level. In 
everyday clinical practice the FPG and preload glucose tests 
are recommended while the postprandial glucose is neglected. 
This pattern of diabetes control is obligatory in many diabetes 
outpatient clinics and hospital wards and any treatment cor-
rection must be based only on that parameters. 
The mutual dependence between the HbA1c value and 
postload glucose was described in 1978, by the time the HbA1c 
became a routine evaluation in diabetic patients. Santiago et 
al. showed then the unequivocal positive correlation between 
HbA1c and the 1- and 2-hour oral glucose tolerance test. The 
analyzed population included patients with normal blood glu-
cose, impaired glucose tolerance and those meeting diabetes 
diagnostic criteria [35]. In 1999 the correlation between HbA1c 
and 2-hour glucose results from the oral glucose tolerance test 
proved to be more pronounced than for FPG in a group of 
patients with type 2 diabetes [36]. Bonara et al. in the 2001 
study showed the pronounced positive correlation between 
HbA1c and the mean diurnal plasma glucose profile in the oral 
glucose tolerance test, and the mean preload and postload glu-
cose result. The highest correlation was observed for the mean 
diurnal glucose value and a slightly higher for the preload 
than for the postload glucose. The correlation was much more 
legible in patients with home care than with clinic care mea-
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surements referring to all evaluated parameters. The probable 
reason is that the patients whose measurements were made in 
clinics might kept a diet more strictly on the days of visits to 
clinics than those who made their measurements at home [37]. 
Moreover, in patients with type 1 diabetes, HbA1c and glucose 
blood levels from the different times of a day showed a clear 
correlation [38]. The patients treated according to the inten-
sive insulinotherapy schedule, performed the 6­point glucose 
profile evaluating fasting, after breakfast, before and after 
lunch, before and after supper blood glucose levels. All the 
measurements defining the mean diurnal glucose blood level, 
the mean glucose preload level and the mean glucose postload 
level showed a strong positive correlation with the HbA1c level, 
with the strongest correlation with the FPG, a glucose level 
test after breakfast and before supper. 
An extraordinary interesting data were obtained from 
the continuous glucose monitoring system (CGMS) in chil-
dren with diabetes type1. The three- consecutive- day survey 
showed that despite relatively good diabetes compensation 
(mean HbA1c 7.7 ±1.4%) and preload glucose levels close to 
normal, the significant postprandial glucose level increase was 
observed. Nearly 90% of all postprandial measurements ex-
ceeded 180 mg/dl and 50% exceeded 300 mg/dl. The mea-
surement with CGMS revealed asymptomatic prolonged noc-
turnal hypoglycemia with glucose levels >60 mg/dl in 70% of 
children [39]. 
The practical aspects of postprandial glucose level mea-
surements were indicated in a large study of patients with 
type 2 diabetes who arrived to the outpatient clinic for the 
glucose blood level evaluation 1–4 hours after meal at home 
[40]. The mean HbA1c level was 8.4 ±2.6%. In the majority 
of patients the diabetes compensation was insufficient because 
HbA1c levels >6.5% in 77% of patients and ≥7.0% in 67% of 
patients were observed. In the study the correlation between 
HbA1c and postprandial glucose was very significant (r = 0.63; 
p <0.001). The correlation was stronger in patients with di-
etary and oral treatment; however, it was also seen in patients 
treated with insulin. HbA1c levels correlating with the mean 
blood glucose level, in the 1–4 hour after a meal measurement 
are shown in table 2 [40]. In patients with glucose blood levels 
measured during the visit 150 mg/dl, surprisingly often HbA1c 
level exceeded 8.0%. In patients with glucose >150 mg/dl af-
ter breakfast, the probability of HbA1c level above 7.0% was 
high (>80%).
The study results show unequivocally that an inappropri-
ate diabetes compensation may be predicted with a high prob-
ability in patients who have a slight postprandial hypergly-
cemia on the upper normal level regarded as acceptable. The 
blood glucose level exceeding 150 mg/dl measured in the out-
patient clinic several hours after a meal seems to be the sign 
of inappropriate diabetes compensation and the indication to 
Table 1. Cardiovascular complications associated with worsening of glycemia control [31]
Study Parameter Group OR/HR/RR (95% CI)






Honolulu Heart Program Fatal IHD 1-hour glucose level
Quintile 5th comparing with quintile 1st
RR: 2.4*
(1.3–4.6)
Islington Diabetes Study IHD 2-hrs glucose OR: 1.44
(1.06–2.00)
Chicago Heart Association 
Detection Project  
in Industry Study






Whitehall, Paris Prospective & 
Helsinki Policemen Study
Fatal CVD 2-hrs glucose




Hoorn Study Fatal CVD 2-hrs glucose
5.8 mmol/l (105 mg%) increase
RR: 3.0**
Funagata Diabetes Study Fatal CVD IGT vs NGT HR: 2.22
(1.08–4.58)
DECODE metaanaliza Fatal CVD 2-hrs glucose HR: 1.27
(0.86–1.88)
* p <0,001, ** p <0,005
CVD – cardiovascular disease, IHD – ischemic heart disease, IGT – impaired glucose tolerance, NGT – normal glucose tolerance, OR – odds 
ratio, HR – hazard ratio, RR – relative risk
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treatment intensifying. That remains particularly important 
when the doctor does not know the current HbA1c level or the 
patient does not submit to home glucose measurements. The 
therapeutic decision is usually unnecessarily delayed in such 
cases. 
The higher is postprandial glucose contribution in he-
moglobin HbA1c the lower is HbA1c concentration, therefore 
the better diabetes is compensated. That was showed in the 
Monnier et al. study where the patients with diabetes type 
2 not treated with insulin were analyzed [1]. Fasting and be-
tween-meal blood glucose levels were evaluated. In the group 
with the highest HbA1c (>10.2%) share of fasting glucose was 
70%, whereas remaining glucose evaluation made 30%. In the 
groups with HbA1c 7.3–10.2%, postprandial glucose contrib-
uted to 50–60% in the HbA1c level. The highest contribu-
tion of postprandial glycemia came to 70% and was observed 
in the group with HbA1c <7.3%. The dependence observed 
might have probably been even stronger and shifted toward 
postprandial glycemia if the blood glucose had been evaluated 
1–2 hours after a meal, that is at the time of the maximal 
postprandial glucose concentration, not later [1]. 
The issue of postprandial glucose contribution to HbA1c 
hemoglobin concentration have remained unnoticed for a 
long time. For years the importance of postprandial glyce-
mia measurement has been underestimated by clinicians and 
the Diabetic Societies establishing diagnostic and treatment 
standards in diabetes. In 2001 the ADA guidelines remarked 
lack of clinical data for the standard postprandial glucose level 
evaluation in diabetic patients, with the exception of pregnant 
patients. In 2004 the ADA recommended the blood glucose 
level evaluation 1–2 hours after a meal in patients with nor-
mal preload glucose but HbA1c above the upper normal limit 
with a purpose of obtaining glucose levels <180 mg/dl. The 
recommendations were repeated in consecutively published 
guidelines. According to the PTD guidelines published in 
2005 and repeated in 2006–2007, glucose level monitoring 
should contain not only the HbA1c, fasting and preload glucose 
evaluation but also the postload glucose measurement with 
the recommended postprandial glycemia level lower than 135 
mg/dl. 
Surprisingly, the postprandial glycemia evaluation has ex-
isted in standard procedure since recently. Even more surprises 
the lack of postprandial glucose evaluation in a routine care in 
many centers. Without these data the correct oral drugs or in-
sulin dose matching seems to be impossible. Unsolved remains 
the issue of frequency of the postprandial glucose tests since 
there are no recommendations in the published standards. In 
2007 the PTD introduced the guideline of glucose profile with 
the 2-hour after a meal glucose test to be performed at least 
once a week in patients treated with insulin and once a month 
in patients treated with oral medications [34]. 
The epidemiological data indicate that the assumed goals 
in diabetes treatment are achieved in the minority of patients. 
In the USA 37% of diabetic adult patients have HbA1c ex-
ceeding 8% and 14% of patients – even 10% [41]. In Sweden, 
with the best metabolic diabetes compensation results, HbA1c 
>7.5% are observed in 27% of patients with type 2 diabetes 
[43]. The routine of postprandial glycemia monitoring seems 
to allow glucose and HbA1c normalization achievement. How-
ever, the monitoring must coexist with a change of diet and a 
possible treatment change or intensification. The postprandial 
glycemia drug target is acarbose, short-acting amplifier of in-
sulin secretion such as repaglinid and nateglinid and fast-act-
ing insulin analogs.
In summary, there are substantial evidences that post-
prandial hyperglycemia is significant in diabetes complication 
development, especially macroangiopathy. High glucose post-
prandial levels may reflect in HbA1c concentration. Relatively 
low HbA1c levels do not necessarily mean that the postpran-
dial glucose check-up is sufficient. There is a need for fasting 
and postprandial glucose blood level monitoring and therapy 
modification with the purpose of achieving the recommended 
HbA1c concentration and stable normalization of glucose di-
urnal level. 
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